{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:22:57Z","timestamp":1791840177198,"version":"4.3.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189494","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:25:13Z","timestamp":1763029513000},"page":"189494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dual faces of angiogenesis: Mechanisms and therapeutic applications"],"prefix":"10.1016","volume":"1880","author":[{"given":"Reza","family":"Izadpanah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard U.","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bbcan.2025.189494_bb0005","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1096\/fj.09-131649","article-title":"Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level","volume":"23","author":"Zhang","year":"2009","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0010","first-page":"178","article-title":"Regulation of tumor angiogenesis by thrombospondin-1","volume":"1765","author":"Ren","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189494_bb0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1097-2765(04)00102-9","article-title":"Endostatin\u2019s antiangiogenic signaling network","volume":"13","author":"Abdollahi","year":"2004","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Sign. Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189494_bb0030","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4940825","article-title":"Oxidative stress and microvascular alterations in diabetic retinopathy: future therapies","volume":"2019","author":"Rodriguez","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.sjopt.2018.05.002","article-title":"Role of oxidative stress, inflammation, hypoxia and angiogenesis in the development of diabetic retinopathy","volume":"32","author":"Al-Kharashi","year":"2018","journal-title":"Saudi J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189494_bb0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"issue":"31","key":"10.1016\/j.bbcan.2025.189494_bb0045","doi-asserted-by":"crossref","first-page":"23779","DOI":"10.1074\/jbc.M110.130658","article-title":"Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity","volume":"285","author":"Iyer","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0050","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Sign. Transduct. Target. Ther."},{"issue":"7347","key":"10.1016\/j.bbcan.2025.189494_bb0055","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189494_bb0060","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-Angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189494_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28145603","article-title":"New crystal form of human Neuropilin-1 b1 fragment with six electrostatic mutations complexed with KDKPPR peptide ligand","volume":"28","author":"Goudiaby","year":"2023","journal-title":"Molecules"},{"issue":"35","key":"10.1016\/j.bbcan.2025.189494_bb0070","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1074\/jbc.RA119.008643","article-title":"N-glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2)","volume":"294","author":"Chandler","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.bbcan.2025.189494_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301121120","article-title":"Gbetagamma activates PIP2 hydrolysis by recruiting and orienting PLCbeta on the membrane surface","volume":"120","author":"Falzone","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189494_bb0080","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189494_bb0090","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/ncomms2683","article-title":"VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation","volume":"4","author":"Hayashi","year":"2013","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189494_bb0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCULATIONAHA.114.009683","article-title":"PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells","volume":"130","author":"Lanahan","year":"2014","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189494_bb0100","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1038\/sj.onc.1210899","article-title":"Thrombin cleaves the high molecular weight forms of basic fibroblast growth factor (FGF-2): a novel mechanism for the control of FGF-2 and thrombin activity","volume":"27","author":"Yu","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189494_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071830","article-title":"Cellular mechanisms of FGF-stimulated tissue repair","volume":"10","author":"Prudovsky","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2025.189494_bb0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.actbio.2019.07.040","article-title":"Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels","volume":"97","author":"Hubka","year":"2019","journal-title":"Acta Biomater."},{"issue":"18","key":"10.1016\/j.bbcan.2025.189494_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25184215","article-title":"Heparan sulfate proteoglycans biosynthesis and post synthesis mechanisms combine few enzymes and few Core proteins to generate extensive structural and functional diversity","volume":"25","author":"Annaval","year":"2020","journal-title":"Molecules"},{"issue":"24","key":"10.1016\/j.bbcan.2025.189494_bb0120","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1101\/gad.844700","article-title":"Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3\u2032-kinase and phospholipase Cgamma signaling pathways","volume":"14","author":"Tallquist","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2025.189494_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.555006","article-title":"SHP-2-induced activation of c-Myc is involved in PDGF-B-regulated cell proliferation and angiogenesis in RMECs","volume":"11","author":"Ma","year":"2020","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cellsig.2010.09.013","article-title":"Platelet-derived growth factor-induced signaling pathways interconnect to regulate the temporal pattern of Erk1\/2 phosphorylation","volume":"23","author":"Jurek","year":"2011","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"42","key":"10.1016\/j.bbcan.2025.189494_bb0140","doi-asserted-by":"crossref","first-page":"40112","DOI":"10.1074\/jbc.M206922200","article-title":"Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha","volume":"277","author":"Chan","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0145","doi-asserted-by":"crossref","first-page":"13603","DOI":"10.1038\/s41598-024-64375-z","article-title":"Notch signaling regulates UNC5B to suppress endothelial proliferation, migration, junction activity, and retinal plexus branching","volume":"14","author":"Raza","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189494_bb0150","article-title":"Canonical Wnt signaling suppresses brain endothelial cell transcytosis to maintain blood-brain barrier integrity","author":"du Maine","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Sign. Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189494_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117177","article-title":"The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds","volume":"178","author":"Bhol","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189494_bb0165","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1172\/JCI93825","article-title":"YAP\/TAZ regulates sprouting angiogenesis and vascular barrier maturation","volume":"127","author":"Kim","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189494_bb0170","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-23-0025","article-title":"Matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal Cancer liver metastases","volume":"83","author":"Zheng","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0175","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189494_bb0180","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189494_bb0185","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/onc.2012.202","article-title":"Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK","volume":"32","author":"Baker","year":"2013","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0190","first-page":"R508","article-title":"The glycocalyx: a central regulator of vascular function","volume":"320","author":"Moore","year":"2021","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.bbcan.2025.189494_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.711003","article-title":"The endothelial Glycocalyx as a double-edged sword in microvascular homeostasis and pathogenesis","volume":"9","author":"Villalba","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2025.189494_bb0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev.bioeng.9.060906.151959","article-title":"The structure and function of the endothelial glycocalyx layer","volume":"9","author":"Weinbaum","year":"2007","journal-title":"Annu. Rev. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0205","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1002\/j.2040-4603.2022.tb00232.x","article-title":"Endothelial Glycocalyx","volume":"12","author":"Foote","year":"2022","journal-title":"Compr. Physiol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0210","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10456-023-09895-4","article-title":"The modes of angiogenesis: an updated perspective","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0215","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pflugers Arch."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.18632\/oncotarget.234","article-title":"Recent advances in anti-angiogenic therapy of cancer","volume":"2","author":"Samant","year":"2011","journal-title":"Oncotarget"},{"issue":"31","key":"10.1016\/j.bbcan.2025.189494_bb0225","article-title":"Red light-triggered anti-Angiogenic and photodynamic combination therapy of age-related macular degeneration","volume":"10","author":"Xu","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0230","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","article-title":"Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors","volume":"156","author":"Croci","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189494_bb0235","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0240","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2020.07.031","article-title":"Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0245","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrclinonc.2012.2","article-title":"Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies","volume":"9","author":"O\u2019Connor","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/bjc.2013.719","article-title":"Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy","volume":"110","author":"Necchi","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s12276-021-00566-2","article-title":"Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies","volume":"53","author":"Mukwaya","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189494_bb0265","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3389\/fphys.2019.01011","article-title":"Imaging the dynamic interaction between sprouting microvessels and the extracellular matrix","volume":"10","author":"Rauff","year":"2019","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbcan.2025.189494_bb0270","doi-asserted-by":"crossref","first-page":"17576","DOI":"10.1038\/srep17576","article-title":"Inhibition of Lysyl oxidases improves drug diffusion and increases efficacy of cytotoxic treatment in 3D tumor models","volume":"5","author":"Schutze","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189494_bb0275","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00432-012-1190-6","article-title":"Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer","volume":"138","author":"Manzoni","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189494_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14133054","article-title":"Basal VEGF-A and ACE plasma levels of metastatic colorectal cancer patients have prognostic value for first-line treatment with chemotherapy plus bevacizumab","volume":"14","author":"Ortiz-Morales","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336918.2024.2395807","article-title":"Liquid biopsy: paving a new avenue for cancer research","volume":"18","author":"Kurma","year":"2024","journal-title":"Cell Adhes. Migr."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189494_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073765","article-title":"Anti-Angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jemt.10249","article-title":"Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix","volume":"60","author":"Li","year":"2003","journal-title":"Microsc. Res. Tech."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189494_bb0300","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1096\/fj.02-0691fje","article-title":"Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation","volume":"17","author":"Hutchings","year":"2003","journal-title":"FASEB J."},{"issue":"7\u20138","key":"10.1016\/j.bbcan.2025.189494_bb0305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-0463.2004.t01-1-apm11207-0806.x","article-title":"The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis","volume":"112","author":"Sund","year":"2004","journal-title":"APMIS"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0310","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189494_bb0315","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.oraloncology.2013.03.452","article-title":"Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma","volume":"49","author":"Gyanchandani","year":"2013","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0320","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/2326-6066.CIR-16-0206","article-title":"Angiopoietin-2 as a biomarker and target for immune checkpoint therapy","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1200\/JCO.2007.13.8099","article-title":"Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107","volume":"26","author":"Grothey","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2025.189494_bb0330","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189494_bb0335","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189494_bb0340","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189494_bb0345","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0355","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9863","key":"10.1016\/j.bbcan.2025.189494_bb0360","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189494_bb0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fcell.2017.00101","article-title":"Therapy for cancer: strategy of combining anti-Angiogenic and target therapies","volume":"5","author":"Comunanza","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"issue":"10326","key":"10.1016\/j.bbcan.2025.189494_bb0370","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189494_bb0375","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 Neovascular age-related macular degeneration trials of Faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"10189","key":"10.1016\/j.bbcan.2025.189494_bb0380","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.bbcan.2025.189494_bb0385","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189494_bb0390","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0395","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ophtha.2019.10.019","article-title":"Treatment patterns for diabetic macular edema: An intelligent research in sight (IRIS(R)) registry analysis","volume":"127","author":"Cantrell","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0400","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","article-title":"Macular atrophy in Neovascular age-related macular degeneration: a randomized clinical trial comparing Ranibizumab and Aflibercept (RIVAL study)","volume":"127","author":"Gillies","year":"2020","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189494_bb0405","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.ophtha.2020.06.006","volume":"127","author":"Venkatesh","year":"2020","journal-title":"Ophthalmology"},{"issue":"18","key":"10.1016\/j.bbcan.2025.189494_bb0410","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189494_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.08.023","article-title":"HIF-2alpha: Achilles\u2019 heel of pseudohypoxic subtype paraganglioma and other related conditions","volume":"86","author":"Tella","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189494_bb0420","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1021\/acs.jmedchem.1c00350","article-title":"New Thyrointegrin \u03b1v\u03b23 antagonist with a scalable synthesis, brain penetration, and potent activity against glioblastoma Multiforme","volume":"64","author":"Hay","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189494_bb0425","article-title":"Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy","volume":"16","author":"Xu","year":"2022","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.bbcan.2025.189494_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123703","article-title":"Recent progress in drug delivery systems for tyrosine kinase inhibitors in the treatment of lung cancer","volume":"650","author":"Korucu Aktas","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0435","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Sign. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0440","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189494_bb0445","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.70058","article-title":"Discovery of a novel alpha isoform of the long-known enzyme LDHA provides new insights into cancer research","volume":"292","author":"Park","year":"2025","journal-title":"FEBS J"},{"key":"10.1016\/j.bbcan.2025.189494_bb0450","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jare.2024.05.001","article-title":"Metabolic reprogramming and interventions in angiogenesis","volume":"70","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0455","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41388-024-03228-5","article-title":"The influence of endothelial metabolic reprogramming on the tumor microenvironment","volume":"44","author":"Kane","year":"2025","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189494_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115064","article-title":"Metabolic reprogramming, sensing, and cancer therapy","volume":"43","author":"Mao","year":"2024","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189494_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112791","article-title":"FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy","volume":"42","author":"Cannell","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189494_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1491099","article-title":"Progress on angiogenic and antiangiogenic agents in the tumor microenvironment","volume":"14","author":"Xu","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0475","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s44178-024-00081-0","article-title":"Antiangiogenic therapy: how far is it to upgrade?","volume":"3","author":"Wang","year":"2024","journal-title":"Holist. Integr. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189494_bb0480","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2024.5473","article-title":"New insights into the role of ubiquitination in angiogenesis (review)","volume":"55","author":"Chen","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0485","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12964-021-00728-9","article-title":"Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma","volume":"19","author":"Zheng","year":"2021","journal-title":"Cell Commun. Signal"},{"issue":"2S","key":"10.1016\/j.bbcan.2025.189494_bb0490","doi-asserted-by":"crossref","first-page":"S1019","DOI":"10.1016\/j.ajog.2020.10.022","article-title":"Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders","volume":"226","author":"Rana","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.bbcan.2025.189494_bb0495","doi-asserted-by":"crossref","first-page":"0207","DOI":"10.34133\/cbsystems.0207","article-title":"A vascularized multilayer Chip reveals shear stress-induced angiogenesis in diverse fluid conditions","volume":"6","author":"Yue","year":"2025","journal-title":"Cyborg Bionic Syst"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bpa.12299","article-title":"The regulation and function of lactate dehydrogenase a: therapeutic potential in brain tumor","volume":"26","author":"Valvona","year":"2016","journal-title":"Brain Pathol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0505","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41433-023-02848-7","article-title":"Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naive and anti-VEGF pretreated patients","volume":"38","author":"Pereira","year":"2024","journal-title":"Eye (Lond.)"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0510","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ophtha.2023.02.001","article-title":"A randomized controlled trial of OPT-302, a VEGF-C\/D inhibitor for Neovascular age-related macular degeneration","volume":"130","author":"Jackson","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbcan.2025.189494_bb0515","doi-asserted-by":"crossref","first-page":"1146399","DOI":"10.3389\/fcell.2023.1146399","article-title":"Cellular heterogeneity and stem cells of vascular endothelial cells in blood vessel formation and homeostasis: insights from single-cell RNA sequencing","volume":"11","author":"Wakabayashi","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189494_bb0520","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41569-022-00770-1","article-title":"Vascular endothelial cell development and diversity","volume":"20","author":"Trimm","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189020","article-title":"Changing landscape of anti-angiogenic therapy: novel approaches and clinical perspectives","volume":"1878","author":"Gacche","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189494_bb0530","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189494_bb0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10456-011-9240-2","article-title":"Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials","volume":"15","author":"Mitsos","year":"2012","journal-title":"Angiogenesis"},{"issue":"15","key":"10.1016\/j.bbcan.2025.189494_bb0540","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202005155","article-title":"Monotherapy and combination therapy using anti-angiogenic nanoagents to fight cancer","volume":"33","author":"Liang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbcan.2025.189494_bb0545","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/132641","article-title":"Tumor angiogenesis: insights and innovations","volume":"2010","author":"Nussenbaum","year":"2010","journal-title":"J. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:29:57Z","timestamp":1781065797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25002367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X25002367"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189494","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual faces of angiogenesis: Mechanisms and therapeutic applications","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189494"}}